as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹2,917.2
Change
+19.8 (0.68%)
Open
₹2,885.0
Prev. Close
₹2,897.4
Day High
₹2,927.0
Day Low
₹2,882.0
Volume Analysis
Traded
124,312
Delivered
62,645
Delivery %
50.39%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Strong operating margin (26.0%)
Weaknesses (1)
- •Promoter holding is falling
Opportunities (2)
- •Strong 3-year revenue growth (21.1%)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹2,980.46 | ₹2,953.73 | ₹2,935.46 | ₹2,908.73 | ₹2,890.46 | ₹2,863.73 | ₹2,845.46 |
| Fibonacci | ₹2,953.73 | ₹2,936.54 | ₹2,925.92 | ₹2,908.73 | ₹2,891.54 | ₹2,880.92 | ₹2,863.73 |
| Camarilla | ₹2,929.58 | ₹2,925.45 | ₹2,921.33 | ₹2,908.73 | ₹2,913.08 | ₹2,908.95 | ₹2,904.83 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+70.09%
1 Week
-0.78%
1 Month
+1.01%
3 Months
+16.92%
6 Months
+71.0%
1 Year
+48.98%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹939.37
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
10.48%
Net margin 16.79% × asset turnover 0.52x × equity multiplier 1.2x
Company Overview
Sector
Healthcare
Market Cap
₹47,846 Cr
P/E (TTM)
41.8
ROE
10.7%
Book Value
₹629.0
Face Value
₹1.0
Source: Screener.in (Consolidated figures) — data as of 24 Sep 2026. Not investment advice.
TopFund Analysis
Gland Pharma Limited holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 72/100. The strongest factor is Financial Strength (100/100), while Valuation (28/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (26.0%); promoter holding is falling. Strong 3-year revenue growth (21.1%).
TopFund Score — Fundamentals Quality
72/100 — GoodData confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company is almost debt free.
- +Company has been maintaining a healthy dividend payout of 39.1%
- −Stock is trading at 4.61 times its book value
- −Company has a low return on equity of 9.29% over last 3 years.
- −Promoter holding has decreased over last 3 years: -6.09%
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Board approved acquiring Gland Pharma USA Inc. for USD 501,208; direct subsidiary by October 31, 2026.
Allotment of 44,193 Equity Shares on exercise of ESOPs
Gland Pharma granted 5,90,249 stock options to 124 employees under ESOP 2025 on September 13, 2026.
Board noted ₹70,000 fine each from NSE and BSE for July 18 director compliance lapse; paid in full.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 1,209 | 1,373 | 1,545 | 1,537 | 1,402 | 1,406 | 1,384 | 1,425 | 1,506 | 1,487 | 1,695 | 1,743 | 1,800 |
| Expenses + | 915 | 1,049 | 1,189 | 1,179 | 1,137 | 1,109 | 1,024 | 1,077 | 1,138 | 1,173 | 1,260 | 1,230 | 1,311 |
| Operating Profit | 294 | 324 | 356 | 359 | 264 | 297 | 360 | 348 | 368 | 314 | 435 | 513 | 489 |
| OPM % | 24.0% | 24.0% | 23.0% | 23.0% | 19.0% | 21.0% | 26.0% | 24.0% | 24.0% | 21.0% | 26.0% | 29.0% | 27.0% |
| Other Income + | 38 | 53 | 37 | 42 | 51 | 60 | 58 | 44 | 58 | 84 | 39 | 111 | 61 |
| Interest | 5 | 6 | 5 | 10 | 6 | 6 | 23 | 7 | 12 | 8 | 4 | 10 | 4 |
| Depreciation | 65 | 81 | 105 | 93 | 92 | 94 | 96 | 96 | 101 | 106 | 108 | 109 | 111 |
| Profit before tax | 261 | 290 | 283 | 298 | 218 | 257 | 299 | 288 | 313 | 284 | 362 | 506 | 435 |
| Tax % | 26.0% | 33.0% | 32.0% | 35.0% | 34.0% | 36.0% | 32.0% | 35.0% | 31.0% | 35.0% | 28.0% | 28.0% | 27.0% |
| Net Profit + | 194 | 194 | 192 | 192 | 144 | 164 | 205 | 187 | 215 | 184 | 261 | 367 | 317 |
| EPS in Rs | 12 | 12 | 12 | 12 | 9 | 10 | 12 | 11 | 13 | 11 | 16 | 22 | 19 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales + | 2,633 | 3,463 | 4,401 | 3,625 | 5,665 | 5,616 | 6,431 | 6,725 |
| Expenses + | 1,678 | 2,161 | 2,890 | 2,600 | 4,332 | 4,348 | 4,801 | 4,974 |
| Operating Profit | 955 | 1,302 | 1,510 | 1,025 | 1,333 | 1,269 | 1,630 | 1,751 |
| OPM % | 36.0% | 38.0% | 34.0% | 28.0% | 24.0% | 23.0% | 25.0% | 26.0% |
| Other Income + | 139 | 135 | 224 | 184 | 170 | 214 | 292 | 296 |
| Interest | 7 | 3 | 5 | 7 | 26 | 42 | 33 | 26 |
| Depreciation | 95 | 99 | 110 | 147 | 345 | 378 | 424 | 434 |
| Profit before tax | 993 | 1,335 | 1,619 | 1,055 | 1,133 | 1,063 | 1,465 | 1,587 |
| Tax % | 22.0% | 25.0% | 25.0% | 26.0% | 32.0% | 34.0% | 30.0% | — |
| Net Profit + | 773 | 997 | 1,212 | 781 | 772 | 699 | 1,027 | 1,129 |
| EPS in Rs | 50 | 61 | 74 | 47 | 47 | 42 | 62 | 68 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 0.0% | 43.0% | 42.0% | 32.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Reserves | 3,631 | 5,887 | 7,141 | 7,942 | 8,707 | 9,134 | 10,341 |
| Borrowings + | 5 | 5 | 5 | 4 | 372 | 314 | 284 |
| Other Liabilities + | 435 | 588 | 671 | 814 | 1,515 | 1,708 | 1,807 |
| Total Liabilities | 4,086 | 6,496 | 7,834 | 8,778 | 10,611 | 11,173 | 12,449 |
| Fixed Assets + | 968 | 954 | 1,502 | 1,571 | 3,947 | 4,147 | 4,492 |
| CWIP | 188 | 338 | 191 | 177 | 238 | 151 | 342 |
| Investments | 0 | 0 | 155 | 0 | 0 | 0 | 0 |
| Other Assets + | 2,929 | 5,204 | 5,986 | 7,030 | 6,426 | 6,875 | 7,614 |
| Total Assets | 4,086 | 6,496 | 7,834 | 8,778 | 10,611 | 11,173 | 12,449 |
| Equity Capital | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 701 | 605 | 791 | 364 | 997 | 915 | 1,031 |
| Cash from Investing Activity + | -761 | -1,520 | -999 | 1,211 | -1,749 | 1,718 | 188 |
| Cash from Financing Activity + | -7 | 1,238 | 35 | 15 | -799 | -433 | -417 |
| Net Cash Flow | -67 | 323 | -174 | 1,590 | -1,552 | 2,199 | 803 |
| CFO/OP | 99 | 70 | 79 | 66 | 98 | 100 | 91 |
| Free Cash Flow | 530 | 377 | 269 | 141 | 599 | 521 | 538 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 14.78% | 13.93% | 13.32% | 8.46% | 8.33% | 8.33% | 8.0% | 7.93% | 7.63% | 7.62% | 7.52% | 9.06% |
| Promoters | 57.86% | 57.86% | 57.86% | 51.83% | 51.83% | 51.83% | 51.83% | 51.83% | 51.83% | 51.83% | 51.83% | 51.77% |
| FII | 4.91% | 4.05% | 3.59% | 6.88% | 4.48% | 5.04% | 6.9% | 7.39% | 7.9% | 7.58% | 7.29% | 8.74% |
| DII | 22.45% | 24.17% | 25.23% | 32.83% | 35.37% | 34.8% | 33.27% | 32.86% | 32.63% | 32.99% | 33.36% | 30.44% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Gland Pharma Limited (this stock) | 47,846 | 41.8 | 4.61 | 10.7% |
| Glaxosmithkline Pharma Lt | 47,864 | 45.4 | 21.08 | 45.6% |
| Anthem Biosciences Ltd | 49,633 | 83.6 | 16.25 | 22.3% |
| Ipca Laboratories Ltd | 50,650 | 36.9 | 6.28 | 15.7% |
| Ajanta Pharma Limited | 44,229 | 39.0 | 9.78 | 27.1% |
| Global Health Limited | 40,516 | 70.8 | 10.24 | 15.2% |
| Narayana Hrudayalaya Ltd. | 38,040 | 44.1 | 8.38 | 20.5% |
Which Mutual Funds Hold Gland Pharma Limited?
Frequently Asked Questions about Gland Pharma Limited
Gland Pharma Limited (GLAND) closed at ₹2,917.2 on NSE on 25 September 2026, up 19.8 (0.68%) from the previous close.
Gland Pharma Limited trades on the NSE (National Stock Exchange of India) under the symbol GLAND.
Gland Pharma Limited has a trailing twelve-month P/E (price-to-earnings) ratio of 41.8.
Gland Pharma Limited has a dividend yield of 0.69%.
Gland Pharma Limited's 52-week high is ₹3,042.0 and its 52-week low is ₹1,574.0.
Gland Pharma Limited has a market capitalisation of ₹47,846 crore.
Gland Pharma Limited has a TopFund Quality Score of 72/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Gland Pharma Limited?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.